Pancreatic Stone Protein Testing Global Market Report 2026

Pancreatic stone protein (PSP) testing is a laboratory blood test used to measure the level of pancreatic stone protein, a biomarker produced by the pancreas and other tissues during physiological stress or cellular dysfunction. It is utilized to evaluate changes in pancreatic stone protein concentration as an indicator of systemic inflammatory response and tissue stress within the body.

The primary product types of pancreatic stone protein testing include assay kits, instruments, reagents, and other product types. Assay kits refer to pre-packaged diagnostic tools utilized to detect and quantify pancreatic stone protein levels in clinical samples for disease assessment. The different technologies include immunoassay based testing, enzyme-linked immunosorbent assay based testing, rapid diagnostic technologies, and other technologies, and the various sample types include blood, serum, plasma, and other sample types. The various applications involved include sepsis diagnosis, pancreatitis diagnosis, and other applications, and they are utilized by several end users such as hospitals, diagnostic laboratories, research institutes, and other end users.

Tariffs are affecting the pancreatic stone protein testing market by increasing the cost of imported assay kits, immunoassay instruments, reagents, and diagnostic consumables used in biomarker testing. This is disrupting global supply chains and raising operational costs for hospitals and diagnostic laboratories, particularly in import-dependent regions such as Asia-Pacific and Latin America. Segments such as immunoassay-based testing kits, automated analyzers, and reagent supplies are most impacted due to reliance on specialized manufacturing hubs. However, tariffs are also encouraging regional production of diagnostic kits, localization of reagent manufacturing, and diversification of supply chains, which support long-term resilience and improved accessibility of PSP testing solutions.

The pancreatic stone protein testing market research report is one of a series of new reports from The Business Research Company that provides pancreatic stone protein testing market statistics, including pancreatic stone protein testing industry global market size, regional shares, competitors with a pancreatic stone protein testing market share, detailed pancreatic stone protein testing market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic stone protein testing industry. This pancreatic stone protein testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreatic stone protein testing market size has grown strongly in recent years. It will grow from $1.22 billion in 2025 to $1.31 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increasing incidence of sepsis and critical care conditions, rising awareness of early disease biomarker testing, expansion of hospital laboratory infrastructure, growth in immunoassay diagnostic adoption, increasing clinical research on pancreatic and inflammatory biomarkers.

The pancreatic stone protein testing market size is expected to see strong growth in the next few years. It will grow to $1.77 billion by 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to rising demand for early sepsis detection tools, increasing adoption of point of care diagnostic testing, growth in precision medicine and biomarker-based diagnostics, expansion of automated laboratory systems, rising investment in critical care diagnostic innovation. Major trends in the forecast period include rising adoption of pancreatic stone protein testing as an early biomarker for sepsis and systemic inflammation detection, increasing use of immunoassay based diagnostic platforms for rapid PSP quantification, growing integration of PSP testing into critical care and emergency diagnostics workflows, expansion of point of care testing devices enabling faster PSP measurement in hospitals, rising demand for multiplex biomarker panels combining PSP with other inflammatory indicators.

The rising incidence of hospital-acquired infections is expected to drive the growth of the pancreatic stone protein testing market going forward. Hospital-acquired infections (HAIs) refer to infections that patients develop while receiving treatment in a hospital or healthcare facility that were not present or incubating at the time of admission. The growing incidence of hospital-acquired infections is mainly driven by increasing antimicrobial resistance, where microorganisms evolve to resist commonly used antibiotics, making infections more difficult to treat and control within healthcare settings. Pancreatic stone protein testing supports the management of hospital-acquired infections by enabling early identification of infection and sepsis risk, allowing timely intervention and improved patient care in hospital environments. For instance, in November 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, hospital-acquired complications (HACs) were reported in 115,000 public hospitalizations (2.0%) and 34,200 private hospitalizations (0.8%) during 2022-23, with healthcare-associated infections accounting for the largest share (37%), followed by delirium (13%) and cardiac complications (12%). Therefore, the rising incidence of hospital-acquired infections is driving the growth of the pancreatic stone protein testing market.

The growing adoption of point-of-care testing (POCT) is expected to support the expansion of the pancreatic stone protein testing market. Point-of-care testing refers to diagnostic procedures conducted at or near the patient care location, allowing healthcare providers to obtain rapid results and make immediate clinical decisions without relying on centralized laboratories. The increasing need for faster diagnostic outcomes, continuous advancements in portable diagnostic devices, and the rising demand for efficient patient management in emergency and critical care environments are contributing to the expansion of POCT. Pancreatic stone protein testing enhances point-of-care testing capabilities by supporting the rapid identification of infection and sepsis risk, enabling earlier medical intervention and improving patient outcomes in hospitals and intensive care units. According to the American Association for Clinical Chemistry, the use of point-of-care diagnostic testing across hospitals and outpatient facilities increased by 12.4% in 2024 compared with the previous year, as reported in March 2025. Consequently, the continued expansion of point-of-care testing is driving demand for pancreatic stone protein testing.

Leading companies operating in the pancreatic stone protein testing market are focusing on developing innovative platforms, such as ultra-rapid point-of-care immunoassay platforms, to enable early and accurate sepsis detection, improve clinical decision-making speed, and reduce patient mortality in critical care settings. Ultra-rapid point-of-care immunoassay platforms are diagnostic systems that rapidly detect specific biomarkers in a patient's sample at or near the bedside using antibody-based reactions, delivering results within minutes instead of hours or days. For instance, in October 2024, Abionic SA, a Switzerland-based in vitro diagnostics company, received approval from the U. S. Food and Drug Administration (FDA) for its IVD CAPSULE Pancreatic Stone Protein (PSP) test. The test is designed for rapid, near-patient detection of PSP levels, enabling early identification of sepsis in critically ill patients. It is based on ultra-rapid point-of-care immunoassay platforms that allow biomarker detection at the bedside through antibody-based reactions, with results delivered within minutes.

Major companies operating in the pancreatic stone protein testing market are Cusabio Technology Llc, Fapon Biotech Inc, BioVendor Laboratorni medicina a. s, RayBiotech Life Inc, Creative Diagnostics Inc, Abnova Corporation, Abionic SA, LASCCO SA, Abbexa Ltd

North America was the largest region in the pancreatic stone protein testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic stone protein testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pancreatic stone protein testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pancreatic stone protein (PSP) testing market consists of revenues earned by entities by providing services such as clinical diagnostic testing services, sepsis risk assessment services, point-of-care testing services, laboratory biomarker analysis services, and monitoring and disease progression services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pancreatic stone protein (PSP) testing market also includes sales of diagnostic software platforms, quality control (QC) materials, sample collection and stabilization tubes, internal quality assurance (IQA) software tools, biomarker data analytics platforms, and pre-analytical sample processing consumables. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pancreatic Stone Protein Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses pancreatic stone protein testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pancreatic stone protein testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pancreatic stone protein testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Assay Kits; Instruments; Reagents; Other Product Types
• 2) By Technology: Immunoassay Based Testing; Enzyme-Linked Immunosorbent Assay Based Testing; Rapid Diagnostic Technologies; Other Technologies
• 3) By Sample Type: Blood; Serum; Plasma; Other Sample Types
• 4) By Application: Sepsis Diagnosis; Pancreatitis Diagnosis; Other Applications
• 5) By End User: Hospitals; Diagnostic Laboratories; Research Institutes; Other End Users
• Subsegments:
• 1) By Assay Kits: Enzyme Linked Immunosorbent Assay Kits; Chemiluminescence Immunoassay Kits; Fluorescence Immunoassay Kits; Rapid Diagnostic Test Kits; Multiplex Assay Kits
• 2) By Instruments: Immunoassay Analyzers; Clinical Chemistry Analyzers; Automated Laboratory Analyzers; Point Of Care Testing Devices; Microplate Readers
• 3) By Reagents: Antibodies; Calibrators; Controls; Buffers; Substrates
• 4) By Other Product Types: Sample Collection Kits; Quality Control Materials; Diagnostic Consumables; Laboratory Accessories; Data Management Software
• Companies Mentioned: Cusabio Technology Llc; Fapon Biotech Inc; BioVendor Laboratorni medicina a.s; RayBiotech Life Inc; Creative Diagnostics Inc; Abnova Corporation; Abionic SA; LASCCO SA; Abbexa Ltd
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.